Cargando…
The Phosphodiesterase-4 Inhibitor Roflumilast, a Potential Treatment for the Comorbidity of Memory Loss and Depression in Alzheimer’s Disease: A Preclinical Study in APP/PS1 Transgenic Mice
BACKGROUND: Depression is highly related to Alzheimer’s disease (AD), yet no effective treatment is available. Phosphodiesterase-4 (PDE4) has been considered a promising target for treatment of AD and depression. Roflumilast, the first PDE4 inhibitor approved for clinical use, improves cognition at...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7727475/ https://www.ncbi.nlm.nih.gov/pubmed/32645141 http://dx.doi.org/10.1093/ijnp/pyaa048 |
_version_ | 1783621089866285056 |
---|---|
author | Wang, Hao Zhang, Fang-fang Xu, Yong Fu, Hua-rong Wang, Xiao-dan Wang, Lei Chen, Wei Xu, Xiao-yan Gao, Yong-feng Zhang, Ji-guo Zhang, Han-Ting |
author_facet | Wang, Hao Zhang, Fang-fang Xu, Yong Fu, Hua-rong Wang, Xiao-dan Wang, Lei Chen, Wei Xu, Xiao-yan Gao, Yong-feng Zhang, Ji-guo Zhang, Han-Ting |
author_sort | Wang, Hao |
collection | PubMed |
description | BACKGROUND: Depression is highly related to Alzheimer’s disease (AD), yet no effective treatment is available. Phosphodiesterase-4 (PDE4) has been considered a promising target for treatment of AD and depression. Roflumilast, the first PDE4 inhibitor approved for clinical use, improves cognition at doses that do not cause side effects such as emesis. METHODS: Here we examined the effects of roflumilast on behavioral dysfunction and the related mechanisms in APPswe/PS1dE9 transgenic mice, a widely used model of AD. Mice at 10 months of age were examined for memory in the novel object recognition and Morris water-maze tests and depression-like behavior in the tail-suspension test and forced swimming test before killing for neurochemical assays. RESULTS: In the novel object recognition and Morris water-maze, APPswe/PS1dE9 mice showed significant cognitive declines, which were reversed by roflumilast at 5 and 10 mg/kg orally once per day. In the tail-suspension test and forced swimming test, the AD mice showed prolonged immobility time, which was also reversed by roflumilast. In addition, the staining of hematoxylin–eosin and Nissl showed that roflumilast relieved the neuronal cell injuries, while terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick-end labelling analysis indicated that roflumilast ameliorated cell apoptosis in AD mice. Further, roflumilast reversed the decreased ratio of B-cell lymphoma-2/Bcl-2-associated X protein and the increased expression of PDE4B and PDE4D in the cerebral cortex and hippocampus of AD mice. Finally, roflumilast reversed the decreased levels of cyclic AMP (cAMP) and expression of phosphorylated cAMP response element-binding protein and brain derived neurotrophic factor in AD mice. CONCLUSIONS: Together, these results suggest that roflumilast not only improves learning and memory but also attenuates depression-like behavior in AD mice, likely via PDE4B/PDE4D-mediated cAMP/cAMP response element-binding protein/brain derived neurotrophic factor signaling. Roflumilast can be a therapeutic agent for AD, in particular the comorbidity of memory loss and depression. |
format | Online Article Text |
id | pubmed-7727475 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-77274752020-12-16 The Phosphodiesterase-4 Inhibitor Roflumilast, a Potential Treatment for the Comorbidity of Memory Loss and Depression in Alzheimer’s Disease: A Preclinical Study in APP/PS1 Transgenic Mice Wang, Hao Zhang, Fang-fang Xu, Yong Fu, Hua-rong Wang, Xiao-dan Wang, Lei Chen, Wei Xu, Xiao-yan Gao, Yong-feng Zhang, Ji-guo Zhang, Han-Ting Int J Neuropsychopharmacol Regular Research Articles BACKGROUND: Depression is highly related to Alzheimer’s disease (AD), yet no effective treatment is available. Phosphodiesterase-4 (PDE4) has been considered a promising target for treatment of AD and depression. Roflumilast, the first PDE4 inhibitor approved for clinical use, improves cognition at doses that do not cause side effects such as emesis. METHODS: Here we examined the effects of roflumilast on behavioral dysfunction and the related mechanisms in APPswe/PS1dE9 transgenic mice, a widely used model of AD. Mice at 10 months of age were examined for memory in the novel object recognition and Morris water-maze tests and depression-like behavior in the tail-suspension test and forced swimming test before killing for neurochemical assays. RESULTS: In the novel object recognition and Morris water-maze, APPswe/PS1dE9 mice showed significant cognitive declines, which were reversed by roflumilast at 5 and 10 mg/kg orally once per day. In the tail-suspension test and forced swimming test, the AD mice showed prolonged immobility time, which was also reversed by roflumilast. In addition, the staining of hematoxylin–eosin and Nissl showed that roflumilast relieved the neuronal cell injuries, while terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick-end labelling analysis indicated that roflumilast ameliorated cell apoptosis in AD mice. Further, roflumilast reversed the decreased ratio of B-cell lymphoma-2/Bcl-2-associated X protein and the increased expression of PDE4B and PDE4D in the cerebral cortex and hippocampus of AD mice. Finally, roflumilast reversed the decreased levels of cyclic AMP (cAMP) and expression of phosphorylated cAMP response element-binding protein and brain derived neurotrophic factor in AD mice. CONCLUSIONS: Together, these results suggest that roflumilast not only improves learning and memory but also attenuates depression-like behavior in AD mice, likely via PDE4B/PDE4D-mediated cAMP/cAMP response element-binding protein/brain derived neurotrophic factor signaling. Roflumilast can be a therapeutic agent for AD, in particular the comorbidity of memory loss and depression. Oxford University Press 2020-07-09 /pmc/articles/PMC7727475/ /pubmed/32645141 http://dx.doi.org/10.1093/ijnp/pyaa048 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of CINP. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Regular Research Articles Wang, Hao Zhang, Fang-fang Xu, Yong Fu, Hua-rong Wang, Xiao-dan Wang, Lei Chen, Wei Xu, Xiao-yan Gao, Yong-feng Zhang, Ji-guo Zhang, Han-Ting The Phosphodiesterase-4 Inhibitor Roflumilast, a Potential Treatment for the Comorbidity of Memory Loss and Depression in Alzheimer’s Disease: A Preclinical Study in APP/PS1 Transgenic Mice |
title | The Phosphodiesterase-4 Inhibitor Roflumilast, a Potential Treatment for the Comorbidity of Memory Loss and Depression in Alzheimer’s Disease: A Preclinical Study in APP/PS1 Transgenic Mice |
title_full | The Phosphodiesterase-4 Inhibitor Roflumilast, a Potential Treatment for the Comorbidity of Memory Loss and Depression in Alzheimer’s Disease: A Preclinical Study in APP/PS1 Transgenic Mice |
title_fullStr | The Phosphodiesterase-4 Inhibitor Roflumilast, a Potential Treatment for the Comorbidity of Memory Loss and Depression in Alzheimer’s Disease: A Preclinical Study in APP/PS1 Transgenic Mice |
title_full_unstemmed | The Phosphodiesterase-4 Inhibitor Roflumilast, a Potential Treatment for the Comorbidity of Memory Loss and Depression in Alzheimer’s Disease: A Preclinical Study in APP/PS1 Transgenic Mice |
title_short | The Phosphodiesterase-4 Inhibitor Roflumilast, a Potential Treatment for the Comorbidity of Memory Loss and Depression in Alzheimer’s Disease: A Preclinical Study in APP/PS1 Transgenic Mice |
title_sort | phosphodiesterase-4 inhibitor roflumilast, a potential treatment for the comorbidity of memory loss and depression in alzheimer’s disease: a preclinical study in app/ps1 transgenic mice |
topic | Regular Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7727475/ https://www.ncbi.nlm.nih.gov/pubmed/32645141 http://dx.doi.org/10.1093/ijnp/pyaa048 |
work_keys_str_mv | AT wanghao thephosphodiesterase4inhibitorroflumilastapotentialtreatmentforthecomorbidityofmemorylossanddepressioninalzheimersdiseaseapreclinicalstudyinappps1transgenicmice AT zhangfangfang thephosphodiesterase4inhibitorroflumilastapotentialtreatmentforthecomorbidityofmemorylossanddepressioninalzheimersdiseaseapreclinicalstudyinappps1transgenicmice AT xuyong thephosphodiesterase4inhibitorroflumilastapotentialtreatmentforthecomorbidityofmemorylossanddepressioninalzheimersdiseaseapreclinicalstudyinappps1transgenicmice AT fuhuarong thephosphodiesterase4inhibitorroflumilastapotentialtreatmentforthecomorbidityofmemorylossanddepressioninalzheimersdiseaseapreclinicalstudyinappps1transgenicmice AT wangxiaodan thephosphodiesterase4inhibitorroflumilastapotentialtreatmentforthecomorbidityofmemorylossanddepressioninalzheimersdiseaseapreclinicalstudyinappps1transgenicmice AT wanglei thephosphodiesterase4inhibitorroflumilastapotentialtreatmentforthecomorbidityofmemorylossanddepressioninalzheimersdiseaseapreclinicalstudyinappps1transgenicmice AT chenwei thephosphodiesterase4inhibitorroflumilastapotentialtreatmentforthecomorbidityofmemorylossanddepressioninalzheimersdiseaseapreclinicalstudyinappps1transgenicmice AT xuxiaoyan thephosphodiesterase4inhibitorroflumilastapotentialtreatmentforthecomorbidityofmemorylossanddepressioninalzheimersdiseaseapreclinicalstudyinappps1transgenicmice AT gaoyongfeng thephosphodiesterase4inhibitorroflumilastapotentialtreatmentforthecomorbidityofmemorylossanddepressioninalzheimersdiseaseapreclinicalstudyinappps1transgenicmice AT zhangjiguo thephosphodiesterase4inhibitorroflumilastapotentialtreatmentforthecomorbidityofmemorylossanddepressioninalzheimersdiseaseapreclinicalstudyinappps1transgenicmice AT zhanghanting thephosphodiesterase4inhibitorroflumilastapotentialtreatmentforthecomorbidityofmemorylossanddepressioninalzheimersdiseaseapreclinicalstudyinappps1transgenicmice AT wanghao phosphodiesterase4inhibitorroflumilastapotentialtreatmentforthecomorbidityofmemorylossanddepressioninalzheimersdiseaseapreclinicalstudyinappps1transgenicmice AT zhangfangfang phosphodiesterase4inhibitorroflumilastapotentialtreatmentforthecomorbidityofmemorylossanddepressioninalzheimersdiseaseapreclinicalstudyinappps1transgenicmice AT xuyong phosphodiesterase4inhibitorroflumilastapotentialtreatmentforthecomorbidityofmemorylossanddepressioninalzheimersdiseaseapreclinicalstudyinappps1transgenicmice AT fuhuarong phosphodiesterase4inhibitorroflumilastapotentialtreatmentforthecomorbidityofmemorylossanddepressioninalzheimersdiseaseapreclinicalstudyinappps1transgenicmice AT wangxiaodan phosphodiesterase4inhibitorroflumilastapotentialtreatmentforthecomorbidityofmemorylossanddepressioninalzheimersdiseaseapreclinicalstudyinappps1transgenicmice AT wanglei phosphodiesterase4inhibitorroflumilastapotentialtreatmentforthecomorbidityofmemorylossanddepressioninalzheimersdiseaseapreclinicalstudyinappps1transgenicmice AT chenwei phosphodiesterase4inhibitorroflumilastapotentialtreatmentforthecomorbidityofmemorylossanddepressioninalzheimersdiseaseapreclinicalstudyinappps1transgenicmice AT xuxiaoyan phosphodiesterase4inhibitorroflumilastapotentialtreatmentforthecomorbidityofmemorylossanddepressioninalzheimersdiseaseapreclinicalstudyinappps1transgenicmice AT gaoyongfeng phosphodiesterase4inhibitorroflumilastapotentialtreatmentforthecomorbidityofmemorylossanddepressioninalzheimersdiseaseapreclinicalstudyinappps1transgenicmice AT zhangjiguo phosphodiesterase4inhibitorroflumilastapotentialtreatmentforthecomorbidityofmemorylossanddepressioninalzheimersdiseaseapreclinicalstudyinappps1transgenicmice AT zhanghanting phosphodiesterase4inhibitorroflumilastapotentialtreatmentforthecomorbidityofmemorylossanddepressioninalzheimersdiseaseapreclinicalstudyinappps1transgenicmice |